J.P. Morgan Notebook: China Rises While US Biomedical Research Under Pressure
Amgen's Bradner explains the rise of China on the global biopharma stage, Flagship's Afeyan calls out US government policies on biomedical research and more in Scrip's daily notebook.
Scrip - January 13, 2026

Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: oral Wegovy launches in the US; the biggest mid-cap catalysts in 2025; small cap pivots and zombie killers last year; commercial headwinds for last year’s launches; and a look at Chinese firms’ global Phase III activity.
Scrip - January 13, 2026

Robot Dogs, Smart Glasses, Digital Companions And Sleep Headbands: AgeTech Shines At CES
In this first roundup from CES, Medtech Insight shines a light on AI-powered technologies that help the aging population live healthier and stay independent longer.
Medtech Insight - January 12, 2026

J&J Says Ottava Represents A ‘New Category’ Of Soft Tissue Robots
Johnson & Johnson is seeking marketing authorization from the US FDA for its Ottava surgical robot for upper abdomen procedures. If granted, Ottava could prove stiff competition for Medtronic and Intuitive.
Medtech Insight - January 12, 2026

Stereotaxis’ MAGiC Catheter Cleared by FDA For Congenital Heart Disease, Eyes Pulse Field Use
The MAGiC catheter works with Stereotaxis’ robotic magnetic navigation technology, which allows physicians to steer catheters through the heart with precision and stability.
Medtech Insight - January 12, 2026

Medtech 2026: Geopolitical Uncertainty Shapes Industry’s Future
As our experts know, the geopolitical and macroeconomic uncertainties reshaping the medtech industry make resilience and innovation more important than ever. Companies are onshoring to sidestep supply chain fragility prompts onshoring, while healthcare systems demand proven value.
Medtech Insight - January 12, 2026

Medtech 2026: Last Year Brought Technical Advances Alongside Regulatory Challenges
Opinions on the medtech industry’s high and low points in 2025 varied. Some experts celebrated innovations and increased investments, while others highlighted negative aspects like staff cuts and challenges at the FDA.
Medtech Insight - January 12, 2026

2026 Year of ‘Clarity’ for US Beauty? Regulatory Reform, FDA Enforcement Strategy Coming Into Focus
Attorneys and consultants who advise beauty firms on federal and state regulations, marketing claims and/or artificial intelligence share their expectations for 2026.
HBW Insight - January 13, 2026

Mabwell’s Humira Biosimilar Approved In Indonesia
The Indonesian health regulator has greenlit Mabwell’s adalimumab biosimilar, marking another global move for the Chinese firm.
Generics Bulletin - January 12, 2026

Orifarm Targets Growth In Generics With New BD Chief
As Denmark’s Orifarm announced the appointment of Jutta Schnirring-Mayer as chief business development and portfolio strategy officer – the latest in a line of management changes under new CEO Mads Fink Eriksen – the firm set out its ambitions to expand its European generics business.
Generics Bulletin - January 12, 2026

PAI Pharma Builds Hospital-Focused Platform With Nivagen Acquisition
Transaction adds sterile injectable manufacturing and strengthens the company’s US-based operations.
Generics Bulletin - January 12, 2026

Inside The Gray Zone Of Pharma Google Ads
A search bar has become one of the most powerful gateways into modern healthcare. The result is a gray zone where advertising practices, consumer trust and public health collide, raising questions about whether digital marketing has outpaced regulation.
In Vivo - January 12, 2026

The Biggest Mid-Cap Catalysts In 2025 – And What Happens Next
Investor enthusiasm for exciting data in 2025 transformed the prospects of a few companies in a single day’s trading – but that enthusiasm sometimes disappeared almost as quickly as it arrived.
In Vivo - January 12, 2026

How One Biotech Built A Three-Continent Model To Navigate US-China Tensions
Pilatus Biosciences' Switzerland-Taiwan-US structure exemplifies how biotechs might navigate US-China tensions, leveraging Chinese manufacturing efficiency while maintaining American investor credibility and partnership opportunities.
In Vivo - January 12, 2026